Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
55 lessons
11mGHRP-6 is the original growth hormone-releasing peptide, a synthetic hexapeptide from 1984 that works on the ghrelin receptor. It reliably raises growth hormone in people, which is why endocrinologists used it as a diagnostic test. What it has never had is a trial showing it improves body composition, recovery or any clinical outcome.
16mGlutathione is a small antioxidant your cells already make. That biological role does not automatically make every supplement or IV drip effective. Here is what it is, how it works, and what human studies actually show, including the limits and risks.
14mSearchers often type "CBL-514 peptide," but Caliway's drug is a first-in-class small molecule in global Phase 3 for abdominal subcutaneous fat. Here is what trials have reported — and what is still unknown.
11mOn November 9, 2026, FDA required a class-wide warning about NAION, a rare optic nerve condition that can cause sudden vision loss. The risk is real enough to label, small in absolute terms, and still debated. Here is the evidence, drug by drug.
10mTwo antibodies that block the myostatin/activin pathway are being tested alongside GLP-1 drugs to protect lean mass. Bimagrumab's phase 2 BELIEVE trial is published in Nature Medicine. Apitegromab is FDA-approved, but only for spinal muscular atrophy. Neither is a peptide or a pill.
9mNAD+ is essential to cells. That does not make every NAD+ treatment effective. A practical guide to IV claims, oral precursors and what human studies actually measured.
9mBefore you trust any peptide source, run the same checklist a pharmacist would: who is accountable, what was tested, by whom, for which batch, and what the paperwork still cannot tell you.
7mThe question arrives at the front desk first. Here is a three-tier script that answers it honestly, cites what exists, and never turns into a claim or a referral to a vendor.
9mMost peptide stigma is not a single hazard. It is three different risks that clinics mash together. Separate them and the conversation with counsel, pharmacy, and medical directors gets shorter.
8mIf your team cannot state the regulatory status of each compound in one clean sentence, the menu is not ready. Here is the three-band model clinics use before counsel finishes the memo.
7mVendor PDFs are not primary sources. Here is the order clinics should read FDA and state board pages so status sheets survive the first counsel review.
9mA GLP-1 program is a months-long titration that happens at the patient's kitchen table. This guide covers the operational pieces clinics need: adherence against the titration schedule, side-effect logs the prescriber reads, refill timing, check-in cadence, and the compounded-product issues FDA has flagged.
10mAdding peptides to a med spa is a licensing, sourcing and documentation problem before it is a marketing one. Here is the operational order: prescriber, pharmacy, regulatory status by compound, consent, and a way to track what patients actually do between visits.
9mA warm hour in a carry-on can matter. Learn cold-chain basics for refrigerated peptides, travel logging, and when to talk with your pharmacist or clinician.
9mA certificate of analysis is not a green light for injection. This guide walks through lot linkage, purity specs, and the questions COAs leave unanswered.
9mGLP-1 access is a medical and logistics puzzle. Know when self-directed research should pause and a licensed clinician should lead product choice and monitoring.
9mPhase 3 data on retatrutide side effects, in plain English: how often nausea, diarrhea, dysesthesia (skin burning), low blood pressure and injection-site reactions showed up by dose, and what the trials don't tell you.
7mA beginner-friendly guide to KPV, its relationship to alpha-MSH, the evidence behind its nominated uses, and the limits of the 2026 PCAC recommendation.
7mA favorable advisory vote is not permission to prescribe or compound. Here is the practical standard telehealth clinics should use after the 2026 PCAC meeting.
8mBPC-157 is still a research compound, but the advisory review makes one thing clear: access, sourcing, and evidence quality now matter as much as the mechanism.
10mDry powder vs mixed liquid changes everything — concentration, storage, and beyond-use timing. This guide explains lyophilized vs reconstituted peptides and what people mean by constituted vs non.
10mRetatrutide may dominate the weight-loss discussion, but the market debate is really about quality control, documentation, and whether a plan can survive real life.
8mPeople searching how to reconstitute eloralintide usually want a retatrutide-style BAC water chart. Here's the honest version — clinical weekly product vs unverified research powder.
7mAmylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.
8mMariTide is Amgen's once-monthly obesity candidate. This beginner guide covers the mechanism framing, Phase 2 headlines, and what serious trackers should log.
7mMonthly conjugates can pack a bigger post-dose GI window. Here's how to think about MariTide tolerability using Phase 2 lessons — without fear content.
8mThe regulatory story matters because it changes what you can trust, what you should track, and why supply chain quality now sits beside mechanism in the BPC-157 debate.
8mBPC-157 has a real research footprint, but most of the confidence in the compound still comes from preclinical work. That gap matters when people start talking about safety like the answer is settled.
Pet owners are hearing more about BPC-157 and TB-500 for recovery. This guide separates the real biology from the social-media hype and shows what actually matters for healing.
8mRegulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.
9mClinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mGLP-1s can slow gastric emptying, which is why surgery teams now ask different questions. The key is to understand the risk without turning it into fear or hype.
8mPeptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
The July 2026 FDA peptide review is important, but it is not an approval event. Here is how to track the meeting, sourcing changes, and protocol decisions without confusing policy movement with clinical proof.
7mThe biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
7mAMA and FDA updates make one thing clear: peptide interest is moving faster than human evidence, dosing standards, and product-quality controls. Use this checklist before trusting a vial.
8mStack stories spread fast because they are visual and emotional. The smarter move is not to copy the protocol. It is to ask better evidence questions.
8mA new ECRI and ISMP warning says popular wellness peptides are being marketed faster than the evidence can support. Here is how to separate compound science from product risk.
8mHealth Canada's 2026 public advisory names unauthorized injectable peptides sold online and explains why product quality, legal status, and medical supervision matter.
8mA new sports medicine review puts injury-recovery peptides in context. Some mechanisms are promising, but human evidence, safety data, and regulatory status still matter.
7mEfsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
7mEDS changes the safety conversation around peptides. GHK-Cu, BPC-157, and TB-500 are discussed for tissue support, but EDS plus cardiac history should stay clinician-led.
8mSeven FDA warning letters in April 2026 show regulators are paying closer attention to online peptide sellers, especially research-use-only marketing that looks like consumer health claims.
7mWomen have unique considerations with peptides, from hormones and cycle changes to muscle retention, recovery, skin health, and tracking.
9mMost peptide users eventually ask: BAC or sterile water? This guide breaks down tradeoffs, timing, and practical decision rules with a peptide-by-peptide reference workflow.
8mIGF-1 LR3 and HGH are often grouped together, but they act at different points in the GH/IGF-1 axis. Here is the protocol-level breakdown for clinicians, athletes, and longevity-focused users.
9mA potential FDA regulatory shift on 14 compounded peptides — including BPC-157 and TB-500 — could reshape who gets access to peptide therapy and how. Here's what the current signals actually mean.
12mExplore the healing peptide BPC-157, nicknamed the 'Wolverine peptide' for its remarkable regenerative properties.
Maximize your peptide investment with proper storage techniques that maintain potency and extend shelf life.
8mProtect yourself by learning how to verify peptide quality, understand testing reports, and avoid dangerous products.
11mDiscover which peptides work synergistically together and how to stack them safely for enhanced benefits.
11mMelanotan 2 is a synthetic hormone analogue from a University of Arizona tanning program. It darkens skin in people, and it also causes erections, nausea and appetite changes. Its relatives became approved drugs. It never did, and the case-report record explains why regulators keep warning about it.
7mLearn how to select the perfect insulin syringe for your peptide protocol with our comprehensive guide.
9mLearn about common peptide side effects, how to minimize them, and when they require attention.
7mLearn how to safely travel with your peptides while maintaining proper storage and navigating legal considerations.
Also available at /blog for legacy links.